Considering that activation of the EGFR pathway is one of the causes of relapse when on anti-angiogenic treatment with BVZ 9, we tested the effect of the combination of BVZ/IFN, one of the first approved anti-angiogenic therapies 19, with the EGFR inhibitor ERLO on the growth of two experimental mRCC tumor cell lines 786-O and A498 cells in mice. Here, EGFR is linked to neoplasm.